Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species

Journal of Clinical Microbiology

Volumn 37, Issue 12, 1999, Pages 3946-3951

  Arikan, Sevtap ^a,b   Lozano Chiu, Mario ^a,c   Paetznick, Victor ^a   Nangia, Sunaina ^a   Rex, John H ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b HACETTEPE UNIVERSITY   (Turkey)

^c GLAXOSMITHKLINE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ITRACONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS; DILUTION; DRUG SENSITIVITY; FUSARIUM; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MICRODILUTION SUSCEPTIBILITY TESTING; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL;

ASPERGILLUS; ASPERGILLUS FUMIGATUS; FUSARIUM; FUSARIUM SOLANI;

EID: 0032721210     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/jcm.37.12.3946-3951.1999     Document Type: Article

References (26)

1. Abruzzo, G. K., A. M. Flattery, C. J. Gill, L. Kong, J. G. Smith, V. B. Pikounis, J. M. Balkovec, A. F. Bouffard, J. F. Dropinski, H. Rosen, H. Kropp, and K. Bartizal. 1997. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob. Agents Chemother. 41: 2333-2338.
2. a. Arikan, S., M. Lozano-Chiu, V. Paetznick, S. Nangia, and J. H. Rex. 1998. Activity of amphotericin B (AMB), itraconazole (ITR), and voriconazole (VOR) against Aspergillus (ASP) and Fusarium (FUS), abstr., J-19, p. 456. In Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
3. Denning, D. W., S. A. Radford, K. L. Oakley, L. Hall, E. M. Johnson, and D. W. Warnock. 1997. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J. Antimicrob. Chemother. 40:401-414.
4. Denning, D. W., K. Venkateswarlu, K. L. Oakley, M. J. Anderson, N. J. Manning, D. A. Stevens, D. W. Warnock, and S. L. Kelly. 1997. Itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 41:1364- 1368.
5. Dupont, B., and E. Drouhet. 1987. Early experience with itraconazole in vitro and in patients: pharmacokinetic studies and clinical results. Rev. Infect. Dis. 9:S71-S76.
6. Espinel-Ingroff, A. 1998. In vitro activity of the new triazote voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J. Clin. Microbiol. 36:198-202.
7. Espinel-Ingroff, A., M. Bartlett, R. Bowden, N. X. Chin, C. Cooper, Jr., A. Fothergill, M. R. McGinnis, P. Menezes, S. A. Messer, P. W. Nelson, F. C. Odds, L. Pasarell, J. Peter, M. A. Pfaller, J. H. Rex, M. G. Rinaldi, G. S. Shankland, T. J. Walsch, and I. Weitzman. 1997. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J. Clin. Microbiol. 35:139-143.
8. Espinel-Ingroff, A., K. Dawson, M. Pfaller, E. Anaissie, B. Breslin, D. Dixon, A. Fothergill, V. Paetznick, J. Peter, M. Rinaldi, and T. Walsh. 1995. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob. Agents Chemother. 39:314-319.
9. Gehrt, A., J. Peter, P. A. Pizzo, and T. J. Walsh. 1995. Effect of increasing inoculum sizes of pathogenic filamentous fungi on MICs of antifungal agents by broth microdilution method. J. Clin. Microbiol. 33:1302-1307.
10. Guarro, J., C. Llop, C. Aguilar, and I. Pujol. 1997. Comparison of in vitro antifungal susceptibilities of conidia and hyphae of filamentous fungi. Antimicrob. Agents Chemother. 41:2760-2762.
11. Jahn, B., E. Martin, A. Stueben, and S. Bhakdi. 1995. Susceptibility testing of Candida albicans and Aspergillus species by a simple microtiter menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay. J. Clin. Microbiol. 33:661-667.
12. Jahn, B., A. Stüben, and S. Bhakdi. 1996. Colorimetric susceptibility testing of Aspergillus fumigatus: comparison of menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide and Alamar Blue tests. J. Clin. Microbiol. 34:2039-2041.
13. Larone, D. H. 1995. Medically important fungi. A guide to identification. ASM Press, Washington, D.C.
14. Lozano-Chiu, M., S. Arikan, F. M. Martin-Diez, V. Paetznick, J. L. Rodriguez-Tudela, and J. H. Rex. 1998. A two-center study of antibiotic medium 3 (AM3) broth for detection of amphotericin B (amB)-resistant isolates of Candida spp. (CAND) and Cryptococcus neoformans (CNEO), abstr. J19b, p. 456. In Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
15. Lozano-Chiu, M., S. Arikan, F. M. Martin-Diez, V. Paetznick, J. L. Rodriguez-Tudela, and J. H. Rex. 1998. Reliability of antibiotic medium 3 (AM3) agar and E-test for detection of amphotericin B (amB)-resistant isolates of Candida spp.: results of a collaborative two-center study, abstr. J-18, p. 455. In Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
16. Murphy, M., E. M. Bernard, T. Ishimaru, and D. Armstrong. 1997. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 41:696-698.
17. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
18. National Committee for Clinical Laboratory Standards. 1998. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi. Proposed standard M38-P. National Committee for Clinical Laboratory Standards, Wayne, Pa.
19. Oakley, K. L., C. B. Moore, and D. W. Denning. 1998. In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B J. Antimicrob. Chemother. 42:91-94.
20. Oakley, K. L., G. Morrisey, and D. W. Denning. 1997. Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrob. Agents Chemother. 41:1504-1507.
21. Pujol, I., J. Guarro, C. Llop, L. Soler, and J. Fernandez-Ballart. 1996. Comparison study of broth macrodilution and microdilution antifungal susceptibility tests for the filamentous fungi. Antimicrob. Agents Chemother. 40:2106-2110.
22. Radford, S. A., E. M. Johnson, and D. W. Warnock. 1997. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob. Agents Chemother. 41:841-843.
23. Rex, J. H., P. W. Nelson, V. L. Paetznick, M. Lozano-Chiu, A. Espinel-Ingroff, and E. J. Anaissie. 1998. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob. Agents Chemother. 42:129-134.
24. Verweij, P. E., K. L. Oakley, J. Morrisej, G. Morrisey, and D. W. Denning. 1998. Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Antimicrob. Agents Chemother. 42:873-878.
25. Yamada, H., S. Kohno, S. Maesaki, H. Koga, M. Kaku. K. Hara, and H. Tanaka. 1993. Rapid and highly reproducible method for antifungal susceptibility testing of Aspergillus species. J. Clin. Microbiol. 31:1009-1012.
26. Zhanel, G. G., J. A. Karlowskj, G. A. J. Harding, T. V. Balko, S. A. Zelenitsky, M. Friesen, A. Kabani, M. Turik, and D. J. Hoban. 1997 In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatityidis, and Aspergillus species. Antimicrob. Agents Chemother. 41:863-865.